Automated office and home phone-transmitted blood pressure recordings in uncontrolled hypertension treated with valsartan and hydrochlorothiazide

References

• Lang T, de Gaudemaris R, Chatellier G, Hamici L, Diene E. Prevalence and therapeutic control of hypertension in 30000 subjects in the workplace. Hypertension 2001; 38: 449–54.
   PubMed Web of Science ®Google Scholar
• Girerd X, Mourad JJ, Vaisse B, Poncelet P, Mallion JM, Herpin D. Estimation of the number of patients treated for hypertension, diabetes or hyperlipidemia in France: FLAHS study 2002. Arch Mal Coeur Vaiss 2003; 96: 750–3.
   PubMedGoogle Scholar
• 2003 European Society of Hypertension- European Society of Cardiology. Guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011–53.
   Google Scholar
• The Seven Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 2003; 289: 2560–72.
   Google Scholar
• Hitzenberger G, Magometschnigg D. Blood pressure charac-teristics of hypertensive patients in Austria as determined byself-monitoring (SCREEN-II). Blood Press 2003; 12: 134–8.
   PubMedGoogle Scholar
• Sever PA, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al for the ASCOT investigators. The preven- tion of coronary events and stroke with atorvastatine in hypertensive subjects with average or below average cholesterol levels. The Anglo-Scandinavian Cardiac Out-comes Trial: Lipid Lowering Arm (ASCOT: LLA). Lancet 2003; 361: 1149–58.
   Google Scholar
• Borzecki AM, Wong AT, Hickey EC, Ash AS, Berlowitz DR. Hypertension control: How well are we doing? Arch Intern Med 2003; 163: 2705–11.
   PubMedGoogle Scholar
• Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003; 326: 1427–31.
   PubMed Web of Science ®Google Scholar
• Muldoon FM, Rutan GH. Defining hypertension never as simple as it seems. J Hypertens 2003; 21: 473–4.
   PubMedGoogle Scholar
• Mengden T, Vetter H, Tisler A, Illyes M. Tele-monitoring of home blood pressure. Blood Press Monit 2001; 6: 185–9.
   PubMedGoogle Scholar
• Deak G, Nemeth Z, Moczar K. Validation of the 24-hour ambulatory blood pressure monitor TensioDay according to the AAMI (1993) and BHS (1993). Report from the 1st Department of Medicine Semmelweis University Budapest, Hungary, 2000.
   Google Scholar
• Landis JR, Koch GG. The measurement of observer agree-ment for categorical data. Biometrics 1977; 33: 159–74.
   PubMed Web of Science ®Google Scholar
• O'Brien E, Asmar R, Beilin L, Imai Y, Mallion JM, Mancia G, et al on behalf of the European Society of HypertensionWorking Group on Blood Pressure Monitoring. J Hypertens 2003; 21: 821–48.
   PubMed Web of Science ®Google Scholar
• Cirée A, Hanon 0, Bureau JM, Mourad JJ, Girerd X. Influence du protocole sur la qualité de l'automesure tensionnelle. Archiv Mal Coeur 2001; 94: 893–6.
   PubMedGoogle Scholar
• Mengden T, Hernandez Medine RM, Beltran B, Alvarez E, Kraft K, Vetter H. Reliability of self-measured blood pressure values by hypertensive patients. Am J Hypertens 1998; 11: 1413–17.
   PubMed Web of Science ®Google Scholar
• Stergiou G, Skeva I, Zourbaki A, Mountokalakis T. Self-monitoring of blood pressure at home: how many measure-ments are needed? J Hypertens 1998; 16: 725–31.
   PubMed Web of Science ®Google Scholar
• Herpin D, Pickering TG, Stergiou GS, De Leeuw P, Germano G. Self-blood pressure monitoring: clinical appli-cations and diagnosis. Blood Press Monit 2000; 5: 131–5.
   PubMed Web of Science ®Google Scholar
• Parati G, Mancia G. White coat effect: semantics, assess-ment and pathophysiological implications. J Hypertens 2003; 21: 481–6.
   PubMedGoogle Scholar
• Parati G, Stergiou G. Self measured and ambulatory blood pressure in assessing the 'white coat' phenomenon. J Hypertens 2003; 21: 677–82.
   PubMed Web of Science ®Google Scholar
• Mancia G, Korlipara K, van Rossum P, Villa G, Silvert B. An ambulatory blood pressure monitoring study of the comparative antihypertensive efficacy of two angiotensin II receptor antagonists, irbesartan and valsartan. Blood Press Monit 2002; 7: 135–42.
   Google Scholar
• Redon J, Lurbe E. Ambulatory blood pressure monitoring during antihypertensive treatment: the case of non-respon-der patients. Blood Press Monit 1996; 1: 299–303.
   PubMedGoogle Scholar
• Wing LMH, Brown MA, Beilin LJ, Ryan P, Reid CM On behalf of the ANBP2 Management Committee and Inves-tigators. 'Reverse white coat hypertension' in older hyper-tensives. J Hypertens 2002; 20: 639–44.
   Google Scholar
• Pickering T, Davidson K, Gem in W, Schwartz JE. Masked hypertension. Hypertension 2002; 40: 795–6.
   PubMed Web of Science ®Google Scholar
• Chatellier G, Dutrey-Dupagne C, Vaur L, Zannad F, Genes N, Elkik F, et al. Home self blood pressure measurement in general practice. The SMART study. Self-measurement for the assessment of the response to trandolapril. Am. J. Hypertens 1996; 9: 644–52.
   Google Scholar
• Belz G. Pharmacological differences among angiotensine II receptor antagonists. Blood Press 2001; 10 Suppl 2: 13–18.
   Google Scholar
• Benz JR, Black HR, Graff A, Reed A, Fitzsimmon S, Shi Y. Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind placebo-con-trolled trial comparing combination therapy with mono-therapy. J Human Hypertens 1998; 12: 861–6.
   Google Scholar
• Jounela AJ, Lilja M, Lumme J, Morlin C, Hoyem A, Wes sel-Aas T, et al. Relation between low dose of hydrochloro-thiazide, antihypertensive effect and adverse effects. Blood Press 1994; 3: 231–5.
   Google Scholar
• Magee PF, Freis ED. Is low dose hydrochlorthiazide effective? Hypertension 1996; 8 Suppl 2: 135–9.
   Google Scholar
• Systolic Hypertension in the Elderly program (SHEP) Coop-erative Research Group. Prevention of stroke by antihyper-tensive drug treatment in older persons with isolated hypertension. Final results. JAMA 1991; 265: 3255–64.
   Google Scholar
• The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 1305–15.BLOOD PRESSURE 2004
   Google Scholar
• Brown MJ, Palmer CR, Castaigne A, De Leeuw, Mancia G, Rosenthal T, et al. Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hyper-tension Treatment (INSIGHT). Lancet 2000; 356: 366–372.
   PubMed Web of Science ®Google Scholar
• Hansson L, Lindholm LH, Ekbom T, Dahlof B, Lanke J, Schersten B, et al. Randomized trial of old and new anti-hypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354: 1751–6.
   PubMed Web of Science ®Google Scholar
• Ogden LG, He J, Lydick E, Whelton PK. Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC VII risk stratification. Hyper-tension 2000; 35: 1021–4.
   Google Scholar